Controlling systemic disease from the gut: intestinal ROS as an upstream driver of systemic inflammation

Area of Science:

• Gastroenterology
• Redox Biology
• Pharmacology

Background:

• Oxidative stress contributes to chronic diseases, but systemic antioxidant therapies have shown limited efficacy.
• The intestine's role in systemic inflammation is recognized, yet the impact of intestinal reactive oxygen species (ROS) remains under-investigated.
• Current antioxidant strategies face challenges with non-selective distribution and interference with essential physiological signaling.

Purpose of the Study:

• To review evidence supporting the targeted scavenging of intestinal ROS.
• To explore the therapeutic potential of gut-confined antioxidant nanoparticles.
• To establish intestinal oxidative stress as a key driver of systemic disease.

Main Methods:

• Utilized orally administered, non-absorbable antioxidant nanoparticles.
• Focused on antioxidants confined to the intestinal lumen, avoiding systemic absorption.
• Evaluated effects across multiple preclinical disease models.

Main Results:

• Selective intestinal ROS scavenging demonstrated profound whole-body physiological effects without systemic drug exposure.
• Gut-localized antioxidants protected the intestinal barrier from oxidative damage.
• Attenuating intestinal oxidative stress prevented systemic inflammation, reduced interleukin-6 levels, and improved outcomes in various disease models, including exercise-induced damage, depression-like behaviors, and cancer cachexia.

Conclusions:

• Intestinal oxidative stress is an upstream factor in systemic disease progression.
• Gut-confined antioxidant intervention represents a safe and mechanistically unique therapeutic strategy.
• This approach offers a new perspective on oral antioxidant therapy, emphasizing intestinal redox control.